Reversed-phase high-performance liquid chromatographic investigation of urinary normal and modified nucleosides of cancer patients.

Post-transcriptional modifications in RNA give rise to free modified ribonucleosides circulating in the blood stream and excreted in urine. Due to their abnormal levels in conjunction with several tumor diseases, they have been suggested as possible tumor markers. The developed RP-HPLC method has been applied to analyze the urinary nucleosides in 34 urinary samples from 15 kinds of cancer patients. The statistical analyses showed the urinary nucleoside excretion, especially modified nucleoside levels, in cancer patients were significantly higher than those in normal healthy volunteers. Factor analysis was used to classify the patients with cancer and normal healthy humans. It was found that using 15 urinary nucleoside levels or only five modified nucleoside levels as data vectors the factor analysis plot displayed two almost separate clusters representing each group.

[1]  G. Nass.  Modified Nucleosides and Cancer , 2011, Recent Results in Cancer Research/Fortschritte der Krebsforschung/Progrès dans les recherches sur Ie cancer.

[2]  I. Selikoff,et al.  Urinary excretion of modified nucleosides in patients with malignant mesothelioma. , 1983, Cancer research.

[3]  K. Higashino,et al.  Urinary pseudouridine as a tumor marker in patients with small cell lung cancer. , 1986, Clinica chimica acta; international journal of clinical chemistry.

[4]  E. Borek.  Toward a universal tumour marker. , 1984, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[5]  A. Niveleau,et al.  Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies. , 1992, Cancer letters.

[6]  Edmund R. Malinowski,et al.  Factor Analysis in Chemistry , 1980 .

[7]  D. Massart.  Chemometrics: A Textbook , 1988 .

[8]  K. Schram,et al.  Urinary excretion of modified nucleosides as biological marker of RNA turnover in patients with cancer and AIDS. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[9]  D. Ettinger,et al.  Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lung. , 1982, European journal of cancer & clinical oncology.

[10]  S. Ishiwata,et al.  Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[11]  C. Speicher,et al.  Elevated nucleoside excretion by patients with nasopharyngeal carcinoma: Preliminary diagnostic/prognostic evaluations , 1982, Cancer.

[12]  H. Liebich,et al.  Quantitation of urinary nucleosides by high-performance liquid chromatography. , 1997, Journal of chromatography. A.

[13]  Guowang Xu,et al.  Analysis of normal and modified nucleosides in urine by capillary electrophoresisa) , 1997 .

[14]  C. Heierli,et al.  [Serum creatinine determination without protein precipitation]. , 1972, Clinica chimica acta; international journal of clinical chemistry.

[15]  R. Lehmann,et al.  Capillary electrophoresis of urinary normal and modified nucleosides of cancer patients. , 1998, Journal of chromatography. A.

[16]  S. D'Ambrosio,et al.  An enzyme-linked immunosorbent assay (ELISA) for the detection and quantitation of the tumor marker 1-methylinosine in human urine. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[17]  K. Kuo,et al.  Patterns of urinary excretion of modified nucleosides. , 1979, Cancer research.